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Objective: Prostate cancer is a common disease with a multifactorial and complex etiology. Genetic
variants inﬂuence the level of matrix metalloproteinase (MMP) gene expression and protein function that
are involved in susceptibility to and the prognosis of several cancers.
Materials and Methods: In this project, we selected 40 patients with prostate cancer and treated them
with androgen-deprivation therapy (ADT). The prostate cancer patients treated with ADT were divided
into two groups, those with a time to progression (TTP) < 12 months and those with a TTP > 12 months.
The DNA from tumors (biopsy), blood, and oral epithelium cells was collected. The polymorphisms of
MMP1 -1607 1G/2G, MMP2 -1306 C/T, MMP3 -1171 5A/6A, MMP8 -799 C/T, and MMP9 -1562 C/T were
selected for genotyping. The association of selected polymorphisms and prognosis of prostate cancer and
efﬁcacy of ADT were analyzed.
Results: Our preliminary results showed that MMP2 polymorphism-associated metastasis of prostate
cancer and MMP 8 polymorphism were associated with the efﬁcacy of ADT (deﬁned by TTP). Further-
more, the association of MMP8 remained signiﬁcant after adjustment for other factors.
Conclusion: The promoter polymorphisms of MMP2 and MMP8 should be genetic markers in the prog-
nosis and TTP of ADT in prostate cancer.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer is the most common form of cancer among men
in North America and Europe,1 and its incidence rate has increased
rapidly in Asia in the past few years.2 Genetics and diet have been
implicated in the development of prostate cancer. Many single
nucleotide polymorphisms (SNPs) have been associated with the
risk of prostate cancer in several genome-wide association studies,
such as the Cancer Genetic Markers of Susceptibility study.3e14
Some genetic polymorphisms are associated with the prognosis
of prostate cancer.15 However, the prognostic value of the prostate
cancer-associated variants has not been well documented.
Genetic variants inﬂuence the level of matrix metalloproteinase
(MMP) gene expression and protein function that are involved ins, Tzu Chi University, Number
an.
u).
ociation. Published by Elsevier Tathe regulation of tumor growth and apoptosis, promotion of
angiogenesis, and induction of the loss of cell adhesion, facilitating
invasion, and metastasis. Inherited variation also inﬂuences the
efﬁcacy of androgen therapy.16 A functional SNP has been reported
in theMMP1 gene promoter consisting of a guanosine (G) insertion
at position 1607. This SNP generates a new 50-GGA-30 core
recognition sequence for members of the Ets family of transcription
factors; the 2G/2G genotype was reported to be linked to an
increased risk of colorectal cancer.17 A common functional poly-
morphism that abolishes an Sp1-binding site has been described
for the promoter region of MMP2 (1306 C/T),18 and the TT geno-
types have been associated with a reduced risk of lung,19 gastric,20
and breast cancer.21 A polymorphism was identiﬁed in the pro-
moter region of the MMP3 gene approximately 1600 bps upstream
from the start of transcription, at position 1171, in which one
allele has a run of six adenosines (6A), while the other has ﬁve
adenosines (5A).22 This polymorphism is associated with a
decreased overall risk of metastasis in head/neck and breast can-
cer.23 An MMP8 -799C-T SNP was suggested in which the minoriwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Characteristics of the study participants.
Characteristics Patients (n)
Clinical T stage at diagnosis
T1 3
T2 10
T3 14
T4 7
Clinical N stage at diagnosis
N0 23
N1 11
Clinical M stage at diagnosis
M0 23
M1 11
Biopsy Gleason score at diagnosis
6 2
7 10
8 16
9 5
Metastasis
No 23
Yes 17
M ¼ metastases; N ¼ nodes; T ¼ tumors.
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ated with the prognosis of breast cancer.25,26 In the MMP9 gene, a
functional SNP (R279Q) that presumably enhances substrate
binding27,28 potentially alters the protein structure of MMP9 and
may have some functional relevance, affecting an individual's
susceptibility to cancer.29,30
In this project, we selected 40 patients with prostate cancer,
collected DNA from tumor (biopsy), blood, or oral epithelium cells,
and analyzed ﬁveMMP genotypes using polymerase chain reaction
and DNA sequencing to ﬁnd causative SNPs. The potential clinical
beneﬁts of this study include ﬁnding causative SNPs and evaluating
individual cancer development, metastasis, and prognosis to
improve the efﬁcacy prediction.
2. Materials and methods
2.1. Patients
A study was conducted using surgical specimens embedded in
parafﬁn, peripheral blood mononuclear cells (PBMC), and oral
swabs from 40 prostate cancer patients who received androgen-
deprivation therapy (ADT) between 1999 and 2010 at the Depart-
ment of Urological Surgery, Chang Gung Memorial Hospital, Keel-
ung, Taiwan. The prostate samples were formalin-ﬁxed and parafﬁn
embedded, and were examined in toto by one uropathologist. All
patients provided informed consent for their participation in the
study and for their biological samples to be genetically analyzed.
The study was approved by the Institutional Board of Ethics of
Chang Gung Memorial Hospital.
2.2. Outcomes of ADT
All enrolled patients had been treated with ADT for non-
localized, hormone-sensitive prostate cancer. Data were collected
on patient and disease baseline characteristics, ADT treatment, and
treatment outcome. The primary outcome variable was time to
progression (TTP) during treatment with ADT. Progression was
deﬁned as two rises in the prostate-speciﬁc antigen (at least 1
month apart) greater than a nadir value while receiving ADT. These
rises did not need to be sequential, but the ﬁrst rise needed to be
greater than the nadir prostate-speciﬁc antigen and the second rise
needed to be greater than both the nadir and the ﬁrst rise. The
testosterone was at a castrate level (< 20 ng/dL). TTP during ADT
was deﬁned as the duration of time from initiation of ADT to the
date of ADT progression or the date of initiation of secondary
hormonal therapy, or was censored among patients who had not
progressed at the date last known to be progression free or the date
of death in patients who died without progression. The prostate
cancer patients treated with ADT were divided into groups, those
with a TTP < 12 months and those with a TTP > 12 months.
2.3. DNA preparation
Genomic DNA was extracted from surgical specimens
embedded in parafﬁn, PBMCs, and oral swabs collected from 40
prostate cancer patients using a QIAamp DNA Mini Kit (QIAGEN,
Valencia, CA, USA) according to the manufacturer's instructions.
The extracted genomic DNA was analyzed using agarose gel elec-
trophoresis and quantitatively determined with spectrophotom-
etry, and stored at 80oC until use.
2.4. SNP genotyping
The polymorphisms of MMP1 -1607 1G/2G, MMP2 -1306 C/T,
MMP3 -1171 5A/6A, MMP8 -799 C/T, and MMP9 -1562 C/T wereselected for genotyping. All SNP genotyping was performed using
TaqMan SNP genotyping assays (ABI; Applied Biosystems Inc.,
Foster City, CA, USA). The primers and probes of selected SNPs were
from an ABI assay on demand kit. Reactions were carried out ac-
cording to the manufacturer's protocol. The probe ﬂuorescence
signal detection was performed using the ABI Prism 7900 Real-
Time Polymerase Chain Reaction System (Applied Biosystems Inc.).
2.5. Statistical analysis
All association analyses between prostate cancer characters and
polymorphisms were tested with the c2 test. Odds ratios and 95%
conﬁdence intervals were calculated from contingency tables.
Other statistical analyses, including student t tests and the Man-
neWhitney U test, were performed with SPSS 11.0 software (SPSS
Inc., Chicago, IL, USA).
3. Results
3.1. Clinical information on patients
The average age of enrolled patients was 79.1 ± 7.7 years
(mean ± standard deviation). The clinical data of six patients
including the Tumor, Node, Metastases stage and Gleason score
from biopsies were not available but their metastasis statuses had
been diagnosed. The Gleason score from one other patient was not
available. All available clinical characteristics of the enrolled pa-
tients are listed in Table 1.
Genotyping of the DNA extracted from surgical specimens
embedded in parafﬁn, PBMCs, and oral swabs of prostate cancer
patients was performed to select MMP polymorphisms. The results
from oral swabs and PBMCs were consistent. The DNA from some
patients showed different genotyping results between cancer tis-
sue and oral swab/PBMCs. The inconsistent genotyping results
were validated with sequencing (Figure 1).
3.2. MMP3 and MMP9 putatively associated with Gleason score
The polymorphisms of MMP3 and MMP9 showed nominal as-
sociations with the Gleason score (Table 2). The data generated by
the small sample size did not lead to a solid conclusion about which
genotype was associated with a high/low level Gleason score.
Figure 1. Sequencing of samples with inconsistent genotypes comparing DNA from peripheral blood mononuclear cells and parafﬁn embedded prostate cancer tissue.
A ¼ adenosine; C ¼ cytosine; F ¼ forward sequence; G ¼ guanosine; P ¼ DNA from parafﬁn embedded tissue; Pxxx ¼ patient enrolled identiﬁcation; R ¼ reverse sequence; S ¼ DNA
from oral swabs; T ¼ thymine.
Figure 1. (continued).
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Figure 1. (continued).
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The polymorphismMMP2 -1306C/T showed an association with
metastasis (Table 3). Prostate cancer patients who were T carriers
(CT and TT) were at a higher risk of developing metastasis than
noncarriers.Table 3
Genotype frequencies of matrix metalloproteinase genes by metastasis.3.4. MMP8 associated with ADT efﬁcacy
The prostate cancer patients were divided into two groups ac-
cording to the efﬁcacy of ADT. Group 1 included 13 patients with a
TTP < 12 months and an average age of 79.7 ± 7.1 years. Group 2Table 2
Genotype frequencies of matrix metalloproteinase genes by Gleason score.
Gene Genotype Gleason score p
6 7 8 9
MMP1 1G/2G 2 4 8 3 0.462
2G/2G 0 6 8 2
MMP2 CC
T carrier 2 6 8 3 0.596
0 4 8 2
MMP3 5T/6T 2 1 6 3 0.052
6T/6T 0 9 10 2
MMP8 A carrier 0 7 9 2 0.283
GG 2 3 7 3
MMP9 CC 1 8 15 2 0.054
T carrier 1 2 1 3
A ¼ adenosine; C ¼ cytosine; G ¼ guanosine; T ¼ thymine.included 27 patients with a TTP > 12 months and an average age of
77.7 ± 9.1 years. No signiﬁcant difference was found in the average
age between groups (t ¼ 0.768, p ¼ 0.447). Five patients in Group 1
and three patients in Group 2 had metastasis. The metastasis rates
in the two groups were signiﬁcantly different (c2 ¼ 4.103,
p ¼ 0.043).
MMP8 polymorphism showed an associationwith the efﬁcacy of
ADT with the c2 test (Table 4). After adjusting for age andGene Genotype No metastasis Metastasis p
MMP1 1G/1G 1 2 0.66
1G/2G 11 8
2G/2G 11 7
MMP2 CC 18 7 0.02
CT 4 10
TT 1 0
CC (ref.) vs. T carrier OR (95% CI)
5.14 (1.29, 20.52)
0.02
MMP3 5T/6T 7 7 0.48
6T/6T 16 10
MMP8 AA 5 3 0.60
AG 6 7
GG 12 7
MMP9 CC 17 15 0.46
CT 5 2
TT 1 0
A ¼ adenosine; C ¼ cytosine; CI ¼ conﬁdence interval; G ¼ guanosine; OR ¼ odds
ratio; ref. ¼ reference; T ¼ thymine.
Table 4
Genotype frequencies of matrix metalloproteinase genes by efﬁcacy of androgen-
deprivation therapy.
Gene Genotype > 12 mo  12 mo p
MMP1 1G/1G 1 2 0.41
1G/2G 14 5
2G/2G 12 6
MMP2 CC 19 6 0.20
CT 7 7
TT 1 0
MMP3 5T/6T 7 7 0.08
6T/6T 20 6
MMP8 AA 6 2 0.03
AG 5 8
GG 16 3
MMP9 CC 21 11 1.00
CT 5 2
TT 1 0
A ¼ adenosine; C ¼ cytosine; G ¼ guanosine; T ¼ thymine.
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with the efﬁcacy of ADT remained signiﬁcant (Table 5).
4. Discussion
In this caseecontrol study, we investigated the association of
SNPs in the MMP1, MMP2, MMP3, MMP8, and MMP9 genes with
metastasis, the Gleason score, and the efﬁcacy of ADT for prostate
cancer. MMP2 -1306 C/T showed an association with metastasis of
prostate cancer and MMP8 -799 C/T was associated with the efﬁ-
cacy of ADT in our study population. The associations ofMMP3 and
MMP9 were weak and ambiguous because of the limited sample
size. MMP polymorphisms should be clinically relevant in the
prognosis of prostate cancer.
MMPs are zinc metalloproteases that degrade the collagens of
the extracellular matrix important in tissue remodeling and repair
during development and inﬂammation. MMPs may alter cell cycle
checkpoint controls, may conceivably promote genomic instability
by affecting cell adhesion,31 and contribute to tumor initiation and
development by altering the cellular microenvironment respon-
sible for facilitating tumor formation.32 A role for MMPs in angio-
genesis has also been advocated.33
Excessive or inappropriate expression of MMPs may contribute
to the pathogenesis of cancer in a wide variety of diseases by
facilitating the degradation of tissues. Currently, > 20 MMPs that
can be categorized by substrate speciﬁcity have been identiﬁed.
Functional polymorphisms associated with characteristics of the
expression of these genes may be used as genetic biomarkers in the
diagnosis and prognosis of neoplasia.34 The genotyping/sequencingTable 5
Odds ratio analysis of matrix metalloproteinase genes' genotypes by efﬁcacy of
androgen-deprivation therapy.
Gene Genotype > 12 mo  12 mo p*
MMP1 1G carrier 15 7 0.37
2G/2G 12 6
MMP2 CC (ref.) 19 6 0.99
T carrier 8 7
MMP3 5T/6T 7 7 0.12
6T/6T 20 6
MMP8 A carrier 11 10 0.02
GG (ref.) 16 3
OR (95% CI) ¼ 12.67 (1.06, 150.62); p ¼ 0.045
MMP9 CC 21 11 0.92
T carrier 6 2
*p value was generated by logistical regression and adjusted by age and metastasis.
A ¼ adenosine; C ¼ cytosine; CI ¼ conﬁdence interval; G ¼ guanosine; OR ¼ odds
ratio; ref. ¼ reference genotype; T ¼ thymine.results of selected polymorphisms of MMPs indicated a few
inconsistent genotypes from the DNA of cancer tissues and blood/
oral swabs. Some of the inconsistent genotypes should be due to
the loss of heterozygosity (heterozygous in blood, homozygous in
cancer tissue), and others may be due to mutations or unknown
reasons. However, the observations suggest that when using MMP
polymorphisms as genetic biomarkers in the diagnosis or prognosis
of cancer, inconsistencies in DNA from different sources (cancer
tissues and blood/oral swabs) should be noted.
The MMP2 -1306 C/T polymorphism has been associated with a
reduced risk of colorectal,35 lung,19 gastric,20 esophageal,36 and
breast carcinomas.21,37 In prostate cancer, the MMP2 -1306 C/T
polymorphism was reported to be associated with the Gleason
score in Brazilian men.38 In this study, we found an association
between metastasis of prostate cancer and MMP2 -1306 C/T poly-
morphism. The association with prognostic characteristics,
including those previouslymentioned for prostate cancer should be
further evaluated.
Hormonal regulation of MMPs has been observed in a variety of
cells.39 Increased MMP expression is generally observed in
hormone-related cancers, although differences can sometimes be
seen according to whether expression was studied at the tran-
scription or translational level, or according to the location of the
expression (e.g., serum or tissue). An increase in MMP mRNA or
protein expression is almost invariably accompanied by an associ-
ation with parameters of poor prognosis.40 MMP8 and MMP9 alter
their expression in inﬂammation-mediated abrogation of androgen
signaling.41 However, the mechanism or role of MMPs in the efﬁ-
cacy of ADT is largely unknown.
In conclusion, our results indicatedMMP2 -1306 C/T showed an
association with metastasis of prostate cancer and MMP8 -799 C/T
was associated with the efﬁcacy of ADT in our study population in
Taiwan. It would be valuable to further investigate the clinical
relevance of MMPs as genetic biomarkers for prostate cancer.
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